Our Insights Oncology Anthony Iannacci 10/20/26 Oncology Anthony Iannacci 10/20/26 Verzenio Has Shown Substantial Efficacy in Liposarcoma Read More Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More Oncology Anthony Iannacci 10/3/22 Oncology Anthony Iannacci 10/3/22 CAR-T Outlook Read More Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More Oncology Anthony Iannacci 5/12/22 Oncology Anthony Iannacci 5/12/22 Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC Read More Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More Oncology Anthony Iannacci 11/4/21 Oncology Anthony Iannacci 11/4/21 Prioritizing Indications: An Analytical Framework Read More Oncology Anthony Iannacci 5/6/21 Oncology Anthony Iannacci 5/6/21 Trodelvy: A New Option for Later Lines TNBC Read More Oncology Anthony Iannacci 10/16/20 Oncology Anthony Iannacci 10/16/20 Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL Read More Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More Older Posts Want to get in touch? Click here
Oncology Anthony Iannacci 10/20/26 Oncology Anthony Iannacci 10/20/26 Verzenio Has Shown Substantial Efficacy in Liposarcoma Read More
Oncology Anthony Iannacci 10/6/26 Oncology Anthony Iannacci 10/6/26 Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC Read More
Oncology Anthony Iannacci 9/15/26 Oncology Anthony Iannacci 9/15/26 BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more Read More
Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More
Oncology Anthony Iannacci 7/14/26 Oncology Anthony Iannacci 7/14/26 Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care Read More
Oncology Anthony Iannacci 7/1/26 Oncology Anthony Iannacci 7/1/26 TROP2 ADCs: A Major Innovation for 1L TNBC Read More
Oncology Anthony Iannacci 6/11/26 Oncology Anthony Iannacci 6/11/26 TP53, the most altered gene in oncology Read More
Oncology Anthony Iannacci 4/7/26 Oncology Anthony Iannacci 4/7/26 Lifyorli Approved in Platinum-Resistant Ovarian Cancer Thanks to a 35% Reduction in Mortality Read More
Oncology Anthony Iannacci 2/13/26 Oncology Anthony Iannacci 2/13/26 Keytruda Grabs its 42nd Approval in PD-L1+ PROC Read More
Oncology, R&D Insights Anthony Iannacci 11/11/25 Oncology, R&D Insights Anthony Iannacci 11/11/25 How Equinox Group Models Drugs in R&D: The Case of Alecensa in 1L ALK+ NSCLC Read More
Oncology, R&D Insights Anthony Iannacci 10/30/25 Oncology, R&D Insights Anthony Iannacci 10/30/25 What indications should we focus on? Read More
Oncology Anthony Iannacci 8/7/25 Oncology Anthony Iannacci 8/7/25 Enhertu is poised to dominate first-line HER2+ breast cancer Read More
Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More
Oncology Anthony Iannacci 5/12/22 Oncology Anthony Iannacci 5/12/22 Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC Read More
Oncology Anthony Iannacci 4/11/22 Oncology Anthony Iannacci 4/11/22 Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC Read More
Oncology Anthony Iannacci 11/4/21 Oncology Anthony Iannacci 11/4/21 Prioritizing Indications: An Analytical Framework Read More
Oncology Anthony Iannacci 5/6/21 Oncology Anthony Iannacci 5/6/21 Trodelvy: A New Option for Later Lines TNBC Read More
Oncology Anthony Iannacci 10/16/20 Oncology Anthony Iannacci 10/16/20 Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL Read More
Oncology, R&D Insights Anthony Iannacci 8/26/20 Oncology, R&D Insights Anthony Iannacci 8/26/20 Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study Read More
